Newbury Pharmaceuticals AB has signed a license agreement for 11 new products.

The agreement is part of Newbury’s long-term strategy to build a pipeline of proprietary and licensed products to become a leading hybrid pharmaceutical company for specialty prescription drugs, innovation and brands with focus on the Scandinavian markets.

The new products belong to a variety of therapeutic categories including Atherothrombotic Events, Anxiety disorders, Benign Prostatic Hyperplasia, Cancer, Deep Vein Thrombosis and Systematic Embolism, Diabetes, Multiple Sclerosis, Multiple Myeloma and Primary Nocturnal Enuresis and includes patented formulation, a sophisticated medical device in the form of a pre-filled multidose pen as well as novelty value added delivery systems. The target markets are Sweden, Denmark and Norway and the products have an aggregated market value of SEK 3.1 billion.

The products will be launched gradually from 3rd quarter of 2021.